TerminatedNot applicableNCT03329404

Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE)

Studying Genetic hemoglobinopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Terumo BCTbio
Principal Investigator
Ned Cosgriff, MD, MD, MPH
Terumo BCT
Intervention
Mirasol Red Blood Cells (MIR RBCs)(device)
Enrollment
9 enrolled
Eligibility
12 years · All sexes
Timeline
20182018

Study locations (9)

Collaborators

United States Department of Defense · Joint Warfighter Medical Research Program · U.S. Army Medical Research and Development Command

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03329404 on ClinicalTrials.gov

Other trials for Genetic hemoglobinopathy

Additional recruiting or active studies for the same condition.

See all trials for Genetic hemoglobinopathy

← Back to all trials